医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Toyoda Gosei Launches UV-C High-Speed Surface Disinfector

2021年08月27日 PM03:00
このエントリーをはてなブックマークに追加


 

KIYOSU, Japan

Toyoda Gosei Co., Ltd. (TOKYO:7282) will launch a “UV-C High-Speed Surface Disinfector,” which uses deep ultraviolet (UV-C) LEDs that effectively kill viruses and bacteria, in November 2021. Preorders of the product will be accepted from September 1.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210826005189/en/

UV-C High-Speed Surface Disinfector (Graphic: Business Wire)

UV-C High-Speed Surface Disinfector (Graphic: Business Wire)

With the recent rise in awareness of infection prevention, Toyoda Gosei is launching various products that disinfect air and surfaces using UV-C LEDs. The UV-C High-Speed Surface Disinfector eliminates more than 99.9% of viruses and bacteria on both top and bottom surfaces of smart phones and other devices in 7 seconds (among fastest times in the world*). The disinfector employs a special optical mechanism to concentrate the irradiating UV-C. It can be used in restaurants, hotels, offices, hospitals and various other places to easily disinfect small personal items upon entry and during personal interactions to improve the hygienic environment.

Toyoda Gosei will continue to contribute to a healthier and safer society.

*According to in-house investigation (as of July 31, 2021)

View source version on businesswire.com: https://www.businesswire.com/news/home/20210826005189/en/

CONTACT

Toyoda Gosei Co., Ltd.

Contact: Chihiro Suzuki

inquiry@mail.toyoda-gosei.co.jp

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Medidata宣布快速扩展其传感器云网络,再添10家卫生技术创新组织
  • ウォルグリーン・ブーツ・アライアンスが戦略的見直しを完了し、好業績のブーツ事業の所有権を保持することを決定
  • OliX Pharmaceuticals Announces IND Submission to U.S. FDA to Evaluate Safety and Tolerability of OLX10212 in Phase 1 Clinical Trial
  • DEXLEVO Strengthens Global Reputation of GOURI at IMCAS, the World’s Largest Beauty Anti-Aging Society
  • Sensorion Announces Approval in Australia to Initiate Proof of Concept Clinical Trial of SENS-401 for Residual Hearing Preservation During Cochlear Implantation